Nothing Special   »   [go: up one dir, main page]

EA200970612A1 - Производные индола в качестве агонистов рецептора s1p1 - Google Patents

Производные индола в качестве агонистов рецептора s1p1

Info

Publication number
EA200970612A1
EA200970612A1 EA200970612A EA200970612A EA200970612A1 EA 200970612 A1 EA200970612 A1 EA 200970612A1 EA 200970612 A EA200970612 A EA 200970612A EA 200970612 A EA200970612 A EA 200970612A EA 200970612 A1 EA200970612 A1 EA 200970612A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
agonists
indol derivatives
indol
derivatives
Prior art date
Application number
EA200970612A
Other languages
English (en)
Other versions
EA017406B1 (ru
Inventor
Махмуд Ахмед
Джэймс Майатт
Дэвид Нортон
Дин Энрю Риверс
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970612(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0625647A external-priority patent/GB0625647D0/en
Priority claimed from GB0707615A external-priority patent/GB0707615D0/en
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA200970612A1 publication Critical patent/EA200970612A1/ru
Publication of EA017406B1 publication Critical patent/EA017406B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I), где один из Rи Rпредставляет собой водород или R, и другой представляет собой группу (а), к способам их получения, фармацевтическим композициям, содержащим их, и их применению для лечения состояний или расстройств, которые опосредуются рецептором S1P1.
EA200970612A 2006-12-21 2007-12-19 Производные индола в качестве агонистов рецептора s1p1 EA017406B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0625647A GB0625647D0 (en) 2006-12-21 2006-12-21 Compounds
GB0707615A GB0707615D0 (en) 2007-04-19 2007-04-19 Compounds
PCT/EP2007/064185 WO2008074821A1 (en) 2006-12-21 2007-12-19 Indole derivatives as s1p1 receptor agonists

Publications (2)

Publication Number Publication Date
EA200970612A1 true EA200970612A1 (ru) 2009-10-30
EA017406B1 EA017406B1 (ru) 2012-12-28

Family

ID=39283563

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970612A EA017406B1 (ru) 2006-12-21 2007-12-19 Производные индола в качестве агонистов рецептора s1p1

Country Status (33)

Country Link
US (1) US8101775B2 (ru)
EP (2) EP2091949B1 (ru)
JP (1) JP5309034B2 (ru)
KR (1) KR101495927B1 (ru)
CN (1) CN103012390B (ru)
AR (1) AR064452A1 (ru)
AT (1) ATE509927T1 (ru)
AU (1) AU2007336224B2 (ru)
BR (1) BRPI0721127A2 (ru)
CA (1) CA2673468C (ru)
CL (1) CL2007003755A1 (ru)
CR (2) CR10922A (ru)
CY (2) CY1111702T1 (ru)
DK (2) DK2206710T3 (ru)
DO (1) DOP2009000133A (ru)
EA (1) EA017406B1 (ru)
ES (1) ES2389879T3 (ru)
HK (2) HK1140761A1 (ru)
HR (2) HRP20110456T1 (ru)
IL (1) IL199187A (ru)
JO (1) JO2701B1 (ru)
MA (1) MA30999B1 (ru)
MX (1) MX2009006882A (ru)
MY (2) MY148470A (ru)
NO (1) NO20092385L (ru)
NZ (1) NZ577387A (ru)
PE (2) PE20081398A1 (ru)
PL (2) PL2206710T3 (ru)
PT (2) PT2206710E (ru)
SG (1) SG177914A1 (ru)
SI (2) SI2091949T1 (ru)
TW (1) TWI393564B (ru)
WO (1) WO2008074821A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2643809C2 (ru) * 2012-02-06 2018-02-06 Сареум Лимитед Модуляторы киназ aurora и flt3

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2003132T3 (pl) 2006-04-03 2014-10-31 Astellas Pharma Inc Pochodne oksadiazolu jako agoniści S1P1
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
AR066095A1 (es) * 2007-04-19 2009-07-22 Glaxo Group Ltd Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
MY172105A (en) 2008-05-14 2019-11-14 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
WO2009151621A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151626A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
TW201011013A (en) 2008-06-20 2010-03-16 Glaxo Group Ltd Compounds
JP5449351B2 (ja) 2008-07-23 2014-03-19 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
ES2522345T3 (es) * 2008-07-23 2014-11-14 Novartis Ag Moduladores del receptor de esfingosina 1 fosfato y su uso en el tratamiento de inflamación muscular
PL2342205T4 (pl) 2008-08-27 2016-12-30 Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych
BRPI0923178A2 (pt) * 2008-12-18 2016-02-16 Merck Serono Sa derivados heterocíclicos de oxadiazol fundidos úteis para o tratamento de esclerose múltipla
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
GB0910667D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0910689D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2011005295A1 (en) * 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
EP3868377A1 (en) 2009-11-13 2021-08-25 Receptos Llc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
US20120283297A1 (en) * 2009-12-18 2012-11-08 Glaxo Wellcome House Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN102884064B (zh) * 2010-03-03 2016-01-13 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
WO2011133734A1 (en) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
US9187437B2 (en) 2010-09-24 2015-11-17 Bristol-Myers Squibb Company Substituted oxadiazole compounds
BR112013019683B1 (pt) 2011-02-07 2022-04-19 Biogen Inc Compostos que modulam s1p, composição farmacêutica, e uso dos mesmos
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX2017008925A (es) 2015-01-06 2017-10-11 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
BR112019001153A2 (pt) * 2016-07-22 2019-04-30 Shijiazhuang Sagacity New Drug Development Co., Ltd. agonista s1p1 e aplicação do mesmo
CA3038106A1 (en) 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN110627778B (zh) * 2018-06-25 2023-01-24 中国科学院上海药物研究所 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
MX2022005014A (es) 2019-10-31 2022-05-16 Idorsia Pharmaceuticals Ltd Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1.
CN115210218A (zh) * 2020-02-11 2022-10-18 先正达农作物保护股份公司 杀有害生物活性的环胺化合物
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939238A1 (de) 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4002466A1 (de) 1990-01-28 1991-10-10 Bayer Ag Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5523312A (en) 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
AU2003276043A1 (en) 2002-06-17 2003-12-31 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
CA2524867A1 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
US7659294B2 (en) 2004-10-22 2010-02-09 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
CA2599348C (en) 2005-02-25 2013-07-23 Ono Pharmaceutical Co., Ltd. Indole compound and use thereof
US7605269B2 (en) 2005-03-23 2009-10-20 Actelion Pharmaceuticals Ltd. Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists
WO2006115188A1 (ja) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited ヘテロ環化合物
US20080306124A1 (en) 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
CN101291908A (zh) 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
PL2003132T3 (pl) 2006-04-03 2014-10-31 Astellas Pharma Inc Pochodne oksadiazolu jako agoniści S1P1
CN101511827B (zh) 2006-09-07 2012-02-01 埃科特莱茵药品有限公司 作为免疫调制剂的吡啶-4-基衍生物
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
AR066095A1 (es) 2007-04-19 2009-07-22 Glaxo Group Ltd Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2643809C2 (ru) * 2012-02-06 2018-02-06 Сареум Лимитед Модуляторы киназ aurora и flt3

Also Published As

Publication number Publication date
MX2009006882A (es) 2009-07-03
AR064452A1 (es) 2009-04-01
ATE509927T1 (de) 2011-06-15
MA30999B1 (fr) 2009-12-01
IL199187A0 (en) 2010-03-28
DK2091949T3 (da) 2011-07-18
PT2091949E (pt) 2011-07-13
JP2010513397A (ja) 2010-04-30
CL2007003755A1 (es) 2008-08-22
CY1113131T1 (el) 2016-04-13
NZ577387A (en) 2012-01-12
EP2091949B1 (en) 2011-05-18
EP2091949A1 (en) 2009-08-26
PE20081398A1 (es) 2008-11-19
MY148470A (en) 2013-04-30
CN103012390B (zh) 2015-08-26
TW200843736A (en) 2008-11-16
SG177914A1 (en) 2012-02-28
SI2206710T1 (sl) 2012-10-30
PL2206710T3 (pl) 2012-11-30
DK2206710T3 (da) 2012-08-27
PT2206710E (pt) 2012-09-10
SI2091949T1 (sl) 2011-08-31
US20100113796A1 (en) 2010-05-06
CR10922A (es) 2009-08-12
KR101495927B1 (ko) 2015-02-25
MY156822A (en) 2016-03-31
EP2206710A1 (en) 2010-07-14
NO20092385L (no) 2009-08-24
CA2673468C (en) 2015-06-02
IL199187A (en) 2015-04-30
ES2389879T3 (es) 2012-11-02
BRPI0721127A2 (pt) 2014-03-11
CN103012390A (zh) 2013-04-03
CR20140316A (es) 2014-08-20
JP5309034B2 (ja) 2013-10-09
HRP20110456T1 (hr) 2011-07-31
EP2206710B1 (en) 2012-07-04
PE20121076A1 (es) 2012-09-05
EA017406B1 (ru) 2012-12-28
US8101775B2 (en) 2012-01-24
AU2007336224B2 (en) 2013-01-10
HRP20120685T1 (hr) 2012-09-30
PL2091949T3 (pl) 2011-10-31
CY1111702T1 (el) 2015-10-07
DOP2009000133A (es) 2009-08-15
JO2701B1 (en) 2013-03-03
KR20090092290A (ko) 2009-08-31
HK1130255A1 (en) 2009-12-24
HK1140761A1 (en) 2010-10-22
CA2673468A1 (en) 2008-06-26
WO2008074821A1 (en) 2008-06-26
TWI393564B (zh) 2013-04-21
AU2007336224A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA200970156A1 (ru) Пиридизиноновые производные
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201100503A1 (ru) Глюкозидные производные и их применения
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA201070039A1 (ru) Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA200971074A1 (ru) Антивирусные соединения
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
EA201071329A1 (ru) Диамидные производные адамантана и их применение
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA200970067A1 (ru) Агонисты ep2
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
EA200800421A1 (ru) Соединения
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
EA200870606A1 (ru) Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU